The European Medicines Agency (EMA) is close to authorizing UCB's new treatment, Bimzelx, for hidradenitis suppurativa. The positive assessment from the Chmp suggests it could be...
AbolerIS Pharma is a biopharmaceutical company focused on revolutionizing immunotherapy for autoimmune and inflammatory diseases. Through an innovative antibody therapy directed against the novel target CD45RC,...